Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
37 Obesity Trials near Victorville, CA
Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Ixekizumab + Tirzepatide for Psoriatic Arthritis
Apple Valley, CaliforniaThe main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:T1DM, Obesity Surgery, IBD, Others
Must Not Be Taking:Insulin, IL-17 Inhibitors
250 Participants Needed
Tirzepatide for Obesity
Apple Valley, CaliforniaThis trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
15374 Participants Needed
Tirzepatide for Psoriatic Arthritis
Apple Valley, CaliforniaThe main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
200 Participants Needed
Retatrutide for Obesity
Victorville, CaliforniaThe main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Recent Heart Attack, Others
10000 Participants Needed
Naltrexone + Bupropion for Obesity
San Bernardino, CaliforniaThis trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent MI, Stroke, Hypertension, Others
Must Not Be Taking:Bupropion, Opioids, MAOIs, Others
8600 Participants Needed
Orforglipron for Type 2 Diabetes and Obesity
Rancho Cucamonga, CaliforniaThis trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
2749 Participants Needed
Lomaira for Childhood Obesity
Loma Linda, CaliforniaThe purpose of this study is to treat toddler obesity by improving the toddler nutritional environment. Parents will participate in a free internet nutrition program and may also take obesity medication. These measures may improve the parental nutritional environment and in turn, improve the toddler nutritional environment as well.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:12 - 75
Sex:All
50 Participants Needed
GSBR-1290 for Obesity
Rancho Cucamonga, CaliforniaThis study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of GSBR-1290 in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to GSBR-1290 or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of GSBR-1290 or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 79
Sex:All
220 Participants Needed
Semaglutide for Weight Management in Obesity
Loma Linda, CaliforniaThis trial tests how well semaglutide helps employees from various backgrounds lose weight compared to other weight-loss medications. It works by making people feel less hungry so they eat less. Semaglutide has been widely studied and approved for chronic weight management due to its efficacy in promoting significant weight loss by suppressing appetite and reducing energy intake.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
500 Participants Needed
Semaglutide + Low-Dose Insulin Glargine for Type 2 Diabetes
Loma Linda, CaliforniaThis study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
568 Participants Needed
Survodutide for Obesity and Fatty Liver Disease
Montclair, CaliforniaThis study is open to adults who are at least 18 years old and have
* presumed or confirmed NASH together with overweight or obesity and
* a body mass index (BMI) of 30 kg/m² or more, or
* a BMI of 27 kg/m² and at least one weight-related health problem.
People with a history of other chronic liver diseases cannot take part in this study.
The purpose of this study is to find out whether a medicine called survodutide helps people living with obesity or overweight and a confirmed or presumed liver disease called nonalcoholic steatohepatitis (NASH) to have less liver fat and to lose weight. Participants are put into 2 groups randomly, which means by chance. 1 group gets different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week for about 1 year. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.
Participants are in the study for about 1 year and 3 months. During this time, it is planned that participants visit the study site up to 13 times and receive 3 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At 3 of the visits, the participants' liver is measured using different imaging methods. The results are compared between the groups to see whether the treatment works.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
187 Participants Needed
Maridebart Cafraglutide for Obesity
Riverside, CaliforniaThe primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 99
Sex:All
3501 Participants Needed
Orforglipron for Obesity
Montclair, CaliforniaThis trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1500 Participants Needed
Orforglipron for Obesity
Montclair, CaliforniaThis trial will test the safety and effectiveness of an oral medication called orforglipron in adults who are obese or overweight and have related health problems. The medication aims to help reduce body weight by possibly affecting appetite or metabolism.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
3000 Participants Needed
GZR18 vs Tirzepatide for Obesity
Montclair, CaliforniaThis is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
285 Participants Needed
GSBR-1290 for Obesity
Montclair, CaliforniaPhase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various GSBR-1290 dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 36-week period.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 79
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Recent Weight Change, Others
Must Not Be Taking:Weight Loss Drugs
82 Participants Needed
CagriSema for Chronic Kidney Disease and Type 2 Diabetes in Obesity
San Dimas, CaliforniaThis trial is testing a new medicine called CagriSema to see if it can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and who are overweight or obese. The study will compare CagriSema to two other medicines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Hereditary Kidney Diseases, Dialysis, Others
Must Be Taking:Ace Inhibitors, Arbs
618 Participants Needed
Retatrutide for Chronic Kidney Disease and Obesity
Montclair, CaliforniaThis trial is testing a medication called retatrutide to see if it can help improve kidney function. The study focuses on people who are overweight or obese and have chronic kidney disease, with or without Type 2 Diabetes. The goal is to find out if this medication can make their kidneys work better.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Obesity Surgery, Type 1 Diabetes, Hepatitis, Others
Must Be Taking:Oral Antihyperglycemics, Basal Insulin
120 Participants Needed
Azelaprag + Tirzepatide for Obesity
Montclair, CaliforniaThis study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety.
Estimated Study Length:
* with the optional prescreening, the study duration may be up to 48 weeks.
* the treatment duration will be 24 weeks followed by 12 weeks follow-up.
* the visit frequency will be every 2 weeks for the first 8 weeks of the treatment period and every 4 weeks thereafter.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55+
Sex:All
220 Participants Needed
CT-388 for Type 2 Diabetes and Obesity
Montclair, CaliforniaThis is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Retinopathy, Neuropathy, Others
Must Be Taking:Metformin, SGLT-2 Inhibitors
360 Participants Needed
IMM01-STEM for Muscle Loss and Fat Gain
Pomona, CaliforniaPlacebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Severe Obesity, Psychiatric Disorders, Others
Must Not Be Taking:Corticosteroids, Others
55 Participants Needed
Maridebart Cafraglutide for Obesity
Pomona, CaliforniaThe primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 99
Sex:All
999 Participants Needed
CagriSema for Obesity
Covina, CaliforniaThis study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes
400 Participants Needed
Retatrutide for Obesity and Cardiovascular Disease
Covina, CaliforniaThis trial is testing a medication called retatrutide in people who have both obesity and heart disease. The study will last over two years to see if the medication is safe and effective.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1800 Participants Needed
Behavioral Intervention for Chronic Disease Prevention
Duarte, CaliforniaThis trial tests the EML Program, which offers free classes on healthy eating and physical activity to underserved communities. The goal is to help participants make better lifestyle choices and reduce their risk of chronic diseases.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
347 Participants Needed
Wellness Coaching for Childhood Obesity
Pasadena, CaliforniaThis trial aims to reduce childhood obesity by using conversation techniques in healthcare settings. The focus is on children aged 2-8 who are overweight or obese, especially from diverse and low-income backgrounds. Healthcare providers will discuss weight management with parents and connect them with lifestyle coaches for additional support through phone calls. These conversation techniques have shown promise in promoting weight loss and positive health behavior changes in both adults and children.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:2 - 8
Sex:All
Key Eligibility Criteria
Disqualifiers:Non-English/Spanish Speakers
6600 Participants Needed
FoodRx for Healthy Eating and Weight Loss
Pasadena, CaliforniaThis is an Randomized controlled trial (RCT) to assess the impact of meal planning and affordable grocery delivery on weight loss, dietary quality and health on members of multigenerational Latino households.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2+
Sex:All
Key Eligibility Criteria
Disqualifiers:Chronic Kidney Disease, Insulin-dependent Diabetes, Others
Must Not Be Taking:Steroids, Antidepressants, Antiseizure
720 Participants Needed
MET097 for Obesity
Anaheim, CaliforniaThe goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity.
The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET097 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET097 or placebo. In Part C, participants will receive once-weekly doses of MET097 or placebo for 12 weeks, followed by a single dose at 2X or 4X to explore the potential for once-monthly dosing.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
262 Participants Needed
MET097 for Obesity
Anaheim, CaliforniaThis study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
225 Participants Needed
Trevogrumab + Garetosmab + Semaglutide for Obesity
Anaheim, CaliforniaThis study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy.
Parts A, B, and C of the study are looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
999 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Obesity clinical trials in Victorville, CA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Obesity clinical trials in Victorville, CA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Victorville, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Victorville, CA for Obesity is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Victorville, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Obesity medical study in Victorville, CA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Obesity clinical trials in Victorville, CA ?
Most recently, we added Lomaira for Childhood Obesity, Eloralintide + Tirzepatide for Obesity and Maridebart Cafraglutide for Obesity to the Power online platform.